Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Effect of Niosomal Encapsulation of Quercetin and Silymarin and their Combination on Dimethylnitrosoamine-induced and Phenobarbital promoted Hepatocellular Carcinoma in Rat Model

Author(s): Devendra S. Shirode, Dinesh J. Raut and Nikita Sarasawat*

Volume 21, Issue 5, 2024

Published on: 25 January, 2024

Article ID: e250124226254 Pages: 13

DOI: 10.2174/0115701638278205231231153851

Price: $65

Abstract

Background: Hepatocellular carcinoma is a particularly dangerous and severe kind of liver cancer. Many anticancer drugs fail to complete the treatment of hepatocellular carcinoma without any side effects. There should be appropriate and without side effective treatments for hepatocellular carcinoma.

Objective: The objective of the current study was to evaluate how quercetin and silymarin in a niosomal formulation affected hepatocyte carcinoma caused by diethylnitrosamine.

Methods: Five groups were created from the thirty male rats. Normal control (untreated group), tumor group (administered dimethylnitrosoamine 200 mg/kg), treatment group I (administered 50 mg/kg of niosomal encapsulated quercetin), treatment group II (administered 50 mg/kg of niosomal encapsulated silymarin), and treatment group III (administered 50 mg/kg of niosomal encapsulated quercetin + silymarin). Then, biochemical estimation, serum analysis, and histopathological examination were carried out.

Results: Treatment group III, treated with niosomal encapsulation of a combination of quercetin + silymarin 50 mg/kg, demonstrated the significant restoration of alpha-fetoprotein and carcinoembryonic antigen and also antioxidants like superoxide dismutase and nitric oxide. The histopathological examination showed improved liver architecture in this group compared to other treatment groups.

Conclusion: Our findings revealed that a potent anticancer effect was observed in treatment group III as niosomal formulation increased the bioavailability of the drug within the body. In order to completely understand the underlying processes and evaluate the therapeutic effectiveness of these chemicals in the therapy of hepatocellular carcinoma, further investigation and clinical trials are required.

Graphical Abstract

[1]
Kumar A, Acharya SK, Dhiman RK. 2019 Update of Indian national association for study of the liver consensus on prevention, diagnosis, and management of hepatocellular carcinoma in India: the puri II. Elsevier 2020.
[http://dx.doi.org/10.1016/j.jceh.2019.09.007]
[2]
Devendra S, Roy S, Tushar P. Evaluation of hepatoprotective effect of leaves of seventy percent ethanolic extract of Albizzia lebbeck in paracetamol induced experimental hepatic damage. Plant Arch 2008.
[3]
Sharafi F, Hasani SA, Alesaeidi S, et al. A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: An updated review. Cancer Cell Int 2022; 22(1): 269.
[http://dx.doi.org/10.1186/s12935-022-02682-z] [PMID: 35999569]
[4]
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019; 16(10): 589-604.
[http://dx.doi.org/10.1038/s41575-019-0186-y] [PMID: 31439937]
[5]
Brown TJ, Mamtani R, Gimotty PA, Karasic TB, Yang YX. Impact of etiology of hepatocellular carcinoma on treatment outcomes in a real-world database. J Clin Oncol 2023; 41(4_suppl): 508-8.
[http://dx.doi.org/10.1200/JCO.2023.41.4_suppl.508]
[6]
Shirode DS, Jain BB, Mahendra Kumar CB. Evaluation of hepatoprotective effect of hugonia mystax leaves in carbon tetrachloride induced liver damage in rats. Plant Arch 2015; 15: 587-92.
[7]
Global Cancer Observatory International Agency for Research on Cancer. Estimated age-standardized incidence rates (World) in 2020, World, both sexes, all ages (excl. NMSC). Available from: https://gco.iarc.fr/today/online-analysis-multi-bars?v=2020&mode=cancer&mode_population=countries&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=0&include_nmsc_other=1&type_multiple=%257B%2522inc%2522%253Atrue%252C%2522mort%2522%253Atrue%252C%2522prev%2522%253Afalse%257D&orientation=horizontal&type_sort=0&type_nb_items=%257B%2522top%2522%253Atrue%252C%2522bottom%2522%253Afalse%257D
[8]
Abdeltawab A, Elsyyad H, Abdelaziz K, El-Beltagy AEF. Therapeutic role of quercetin against experimentally induced hepatocellular carcinoma in female albino rats and their offspring. JBAAR 2021; 7(4): 176-97.
[http://dx.doi.org/10.21608/jbaar.2021.209005]
[9]
Liao CY, Lee CC, Tsai C, et al. Novel investigations of flavonoids as chemopreventive agents for hepatocellular carcinoma. BioMed Res Int 2015; 2015: 1-26.
[http://dx.doi.org/10.1155/2015/840542] [PMID: 26858957]
[10]
Didier AJ, Stiene J, Fang L, Watkins D, Dworkin LD, Creeden JF. Antioxidant and anti-tumor effects of dietary vitamins A, C, and E. Antioxidants 2023; 12(3): 632.
[http://dx.doi.org/10.3390/antiox12030632] [PMID: 36978880]
[11]
Gibellini L, Pinti M, Nasi M, et al. Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med 2011; 2011: 1-15.
[http://dx.doi.org/10.1093/ecam/neq053] [PMID: 21792362]
[12]
Singh P, Arif Y, Bajguz A, Hayat S. The role of quercetin in plants. Plant Physiol Biochem 2021; 166: 10-9.
[http://dx.doi.org/10.1016/j.plaphy.2021.05.023] [PMID: 34087741]
[13]
Seufi AM, Ibrahim SS, Elmaghraby TK, Hafez EE. Preventive effect of the flavonoid, quercetin, on hepatic cancer in rats via oxidant/antioxidant activity: Molecular and histological evidences. J Exp Clin Cancer Res 2009; 28(1): 80.
[http://dx.doi.org/10.1186/1756-9966-28-80] [PMID: 19519916]
[14]
Mahmud AR, Ema TI, Siddiquee MFR, et al. Natural flavonols: Actions, mechanisms, and potential therapeutic utility for various diseases. Beni Suef Univ J Basic Appl Sci 2023; 12(1): 47.
[http://dx.doi.org/10.1186/s43088-023-00387-4] [PMID: 37216013]
[15]
Zhou Y, Gu K, Zhou F. Dietary flavonoid intake and cancer mortality: A population-based cohort study. Nutrients 2023; 15(4): 976.
[http://dx.doi.org/10.3390/nu15040976] [PMID: 36839330]
[16]
Raut DJ, Shirode DS, Deokar SS, et al. Quercetin and silymarin loaded niosomal formulation with synergistic effect on hep G2 cell lines. Lat Am J Pharm 2023; 42: 347-54.
[17]
Wendlocha D, Krzykawski K, Mielczarek-Palacz A, Kubina R. Selected flavonols in breast and gynecological cancer: A systematic review. Nutrients 2023; 15(13): 2938.
[http://dx.doi.org/10.3390/nu15132938] [PMID: 37447264]
[18]
Fallah M, Davoodvandi A, Nikmanzar S, et al. Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer. Biomed Pharmacother 2021; 142: 112024.
[http://dx.doi.org/10.1016/j.biopha.2021.112024] [PMID: 34399200]
[19]
Féher J, Lengyel G. Silymarin in the prevention and treatment of liver diseases and primary liver cancer. Curr Pharm Biotechnol 2012; 13(1): 210-7.
[http://dx.doi.org/10.2174/138920112798868818] [PMID: 21466434]
[20]
Singh M, Kadhim MM, Turki Jalil A, et al. A systematic review of the protective effects of silymarin/silibinin against doxorubicin-induced cardiotoxicity. Cancer Cell Int 2023; 23(1): 88.
[http://dx.doi.org/10.1186/s12935-023-02936-4] [PMID: 37165384]
[21]
Koushki M, Farrokhi Yekta R, Amiri-Dashatan N. Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid. J Funct Foods 2023; 104: 105502.
[http://dx.doi.org/10.1016/j.jff.2023.105502]
[22]
Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45(4): 529-38.
[http://dx.doi.org/10.1016/j.jhep.2006.05.013] [PMID: 16879891]
[23]
Ramakrishnan G, Augustine TA, Jagan S, Vinodhkumar R, Devaki T. Effect of silymarin on N-nitrosodiethylamine induced hepatocarcinogenesis in rats. Exp Oncol 2007; 29(1): 39-44.
[PMID: 17431387]
[24]
Chandra YP, Viswanathswamy AHM. Chemo preventive effect of rutin against n-nitrosodiethylamine-induced and phenobarbital- promoted hepatocellular carcinoma in wistar rats. Indian J Pharm Educ Res 2018; 52(1): 78-86.
[http://dx.doi.org/10.5530/ijper.52.1.9]
[25]
Kumar KA, Vijayalakshmi K, Saravanan D. Effect of Punica granatum peel and Vitis vinifera seeds on biochemical indices in DEN induced hepatocellular carcinoma in rats. RJPT 2019; 12(6): 2758.
[http://dx.doi.org/10.5958/0974-360X.2019.00462.1]
[26]
Kumar AK, K V. Protective effect of Punica granatum peel and Vitis vinifera seeds on DEN-induced oxidative stress and hepatocellular damage in rats. Appl Biochem Biotechnol 2015; 175(1): 410-20.
[http://dx.doi.org/10.1007/s12010-014-1276-5] [PMID: 25304489]
[27]
Newman DJ. Natural products as leads to potential drugs: An old process or the new hope for drug discovery? J Med Chem 2008; 51(9): 2589-99.
[http://dx.doi.org/10.1021/jm0704090] [PMID: 18393402]
[28]
Versée V, Barel AO. Rat α-foetoprotein. Purification, physicochemical characterization, oestrogen-binding properties and chemical modification of the thiol group. Biochem J 1978; 175(1): 73-81.
[http://dx.doi.org/10.1042/bj1750073] [PMID: 83865]
[29]
El Sadda RR, Elshahawy ZR, Saad EA. Biochemical and pathophysiological improvements in rats with thioacetamide induced-hepatocellular carcinoma using aspirin plus vitamin C. BMC Cancer 2023; 23(1): 175.
[http://dx.doi.org/10.1186/s12885-023-10644-5] [PMID: 36809998]
[30]
Pietta PG. Flavonoids as antioxidants. J Nat Prod 2000; 63(7): 1035-42.
[http://dx.doi.org/10.1021/np9904509] [PMID: 10924197]
[31]
Al-Harbi SA. Synthesis and characterization of nano crystallite carboxamide-based iron(III) complexes: SOD mimetic activity, antibacterial and anticancer activity and molecular docking study. J Biomol Struct Dyn 2023; 1-23.
[http://dx.doi.org/10.1080/07391102.2023.2243341] [PMID: 37552248]
[32]
Bahrami S, Shahriari A, Tavalla M, Azadmanesh S, Hamidinejat H. Blood levels of oxidant/antioxidant parameters in rats infected with Toxoplasma gondii. Oxid Med Cell Longev 2016; 2016: 1-6.
[http://dx.doi.org/10.1155/2016/8045969] [PMID: 27746857]
[33]
Jabłońska E, Kiersnowska-Rogowska B, Ratajczak W, Rogowski F, Sawicka-Powierza J. Reactive oxygen and nitrogen species in the course of B-CLL. Adv Med Sci 2007; 52: 154-8.
[PMID: 18217409]
[34]
Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocllular carcinoma based on alterd profiles of alpha - fetoprotein. N Engl J Med 1993; 328(25): 1802-6.
[http://dx.doi.org/10.1056/NEJM199306243282502]
[35]
Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive α-fetoprotein and des-γ-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 2007; 52(3): 776-82.
[http://dx.doi.org/10.1007/s10620-006-9541-2] [PMID: 17253135]
[36]
Shirode DS, Powar PV, Chaudhari SP, Jain BB. Effect of Hugonia mystax leaves on histopathological studies, tissue glutathione and lipid peroxide levels of rat liver. IJISRT 2019; 4(11)
[37]
Chiu FY, Yen Y. Imaging biomarkers for clinical applications in neuro-oncology: Current status and future perspectives. Biomark Res 2023; 11(1): 35.
[http://dx.doi.org/10.1186/s40364-023-00476-7] [PMID: 36991494]
[38]
Omar MA, Omran MM, Farid K, et al. Biomarkers for hepatocellular carcinoma: From origin to clinical diagnosis. Biomedicines 2023; 11(7): 1852.
[http://dx.doi.org/10.3390/biomedicines11071852] [PMID: 37509493]
[39]
Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2015; 21(37): 10573-83.
[http://dx.doi.org/10.3748/wjg.v21.i37.10573] [PMID: 26457017]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy